We’re improving your experience!

×

Starting April 21, you’ll be asked to log in or sign up for a free account after viewing 10 content pages each month.

Don’t worry—creating an account is quick and easy, and it comes with added benefits! Once logged in, you’ll not only continue accessing the content you already enjoy, but you’ll also unlock exclusive features like interactive donut plots for variant protein effects and variant impacts across the gene.

Stay tuned for these updates, and thank you for being part of our community!

Clinical Trial Detail

Contact

Missing content? – Request curation!

Request curation for specific Genes, Variants, or PubMed publications.

Have questions, comments, or suggestions? - Let us know!

Email us at : ckbsupport@genomenon.com

NCT ID NCT05583552
Title Study to Evaluate Imetelstat in Patients With High-Risk MDS or AML Failing HMA-based Therapy (IMpress)
Acronym IMpress
Recruitment Active, not recruiting
Gender both
Phase Phase II
Variant Requirements No
Sponsors GCP-Service International West GmbH
Indications
Therapies
Age Groups: senior | adult
Covered Countries FRA | DEU | AUS

Facility Status City State Zip Country Details
Royal Adelaide Hospital Adelaide Australia Details
Royal Brisbane and Women's Hospitals Brisbane Australia Details
Linear Clinical Research Nedlands Australia Details
CHU Nantes - Hôtel Dieu Nantes France Details
Hôpital Archet 1 Nice France Details
Hôpital Saint-Louis Paris France Details
CHU de Toulouse Toulouse France Details
Marien Hospital Düsseldorf Düsseldorf Germany Details
Universität Jena, Medizinische Fakultät Jena Germany Details
Universität Leipzig, Medizinische Fakultät Leipzig Germany Details
Klinikum rechts der Isar München Germany Details
*Shaded cells indicate that there was no data available from clinicaltrials.gov for the field